Combination of the mTOR inhibitor RAD001 with temozolomide and radiation effectively inhibits the growth of glioblastoma cells in culture

Burckel,Hélène; Josset,Elodie; Denis,Jean-Marc; Gueulette,John; Slabbert,Jakobus; Noël,Georges; Bischoff,Pierre

doi:10.3892/or.2014.3590

Combination of the mTOR inhibitor RAD001 with temozolomide and radiation effectively inhibits the growth of glioblastoma cells in culture

Authors:
- Hélène Burckel
- Elodie Josset
- Jean-Marc Denis
- John Gueulette
- Jakobus Slabbert
- Georges Noël
- Pierre Bischoff
View Affiliations

Affiliations: EA 3430, University of Strasbourg, Centre Paul Strauss, Strasbourg, France, MIRO, Catholic University of Louvain, Brussels, Belgium, iThemba LABS, Somerset West, South Africa
Published online on: November 4, 2014 https://doi.org/10.3892/or.2014.3590
Pages: 471-477

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The present in vitro study aimed to assess the effects of combining the mTOR inhibitor RAD001 and temozolomide (TMZ) together with irradiation by either low-linear energy transfer (LET) radiation (γ-rays) or high-LET radiation (fast neutrons) on the growth and cell survival of the human glioblastoma cell line U-87. We observed a strong decrease in cell proliferation along with a concomitant increase in cell death as a function of the radiation dose. As expected, high-LET radiation was more effective and induced more sustained damage to DNA than low-LET radiation. While RAD001 in association with TMZ induced autophagic cell death, additional combination with either type of radiation did not further increase its occurrence. On the contrary, apoptosis remained at a low level in all experimental groups.

View Figures

View References

1	Emdad L, Qadeer ZA, Bederson LB, Kothari HP, Uzzaman M and Germano IM: Is there a common upstream link for autophagic and apoptotic cell death in human high-grade gliomas? Neuro Oncol. 13:725–735. 2011. View Article : Google Scholar : PubMed/NCBI
2	Maucort-Boulch D, Baron MH, Pommier P, Weber DC, Mizoe JE, Rochat J, Boissel JP, Balosso J, Tsuji H and Amsallem E: Rationale for carbon ion therapy in high-grade glioma based on a review and a meta-analysis of neutron beam trials. Cancer Radiother. 14:34–41. 2010. View Article : Google Scholar
3	Begg AC, Stewart FA and Vens C: Strategies to improve radiotherapy with targeted drugs. Nat Rev Cancer. 11:239–253. 2011. View Article : Google Scholar : PubMed/NCBI
4	Scaringi C, Enrici RM and Minniti G: Combining molecular targeted agents and radiation therapy for malignant gliomas. Onco Targets Ther. 6:1079–1095. 2013.
5	Chinnaiyan P, Won M, Wen PY, Rojiani AM, Wendland M, Dipetrillo TA, Com BW and Mehta MP: RTOG 0913: a phase 1 study of daily everolimus (RAD001) in combination with radiation therapy and temozolomide in patients with newly diagnosed glioblastoma. Int J Radiat Oncol Biol Phys. 86:880–884. 2013. View Article : Google Scholar : PubMed/NCBI
6	Zhang M, Herion TW, Timke C, Han N, Hauser K, Weber KJ, Peschke P, Wirkner U, Lahn M and Huber PE: Trimodal glioblastoma treatment consisting of concurrent radiotherapy, temozolomide and the novel TGF-β receptor I kinase inhibitor LY2109761. Neoplasia. 13:537–549. 2011.PubMed/NCBI
7	Sarkaria JN, Galanis E, Wu W, Peller PJ, Giannini C, Brown PD, Uhm JH, McGraw S, Jaeckle KA and Buckner JC: North central cancer treatment group phase I trial N057K of everolimus (RAD001) and temozolomide in combination with radiation therapy in patients with newly diagnosed glioblastoma multiforme. Int J Radiat Oncol Biol Phys. 81:468–475. 2011. View Article : Google Scholar
8	Annovazzi L, Mellai M, Caldera V, Valente G, Tessitore L and Schiffer D: mTOR, S6 and AKT expression in relation to proliferation and apoptosis/autophagy in glioma. Anticancer Res. 29:3087–3094. 2009.PubMed/NCBI
9	Dancey J: mTOR signaling and drug development in cancer. Nat Rev Clin Oncol. 7:209–219. 2010. View Article : Google Scholar : PubMed/NCBI
10	Lee JJ, Kim BC, Park MJ, Lee YS, Kim YN, Lee BL and Lee JS: PTEN status switches cell fate between premature senescence and apoptosis in glioma exposed to ionizing radiation. Cell Death Differ. 18:666–677. 2011. View Article : Google Scholar :
11	Gueulette J, Slabbert JP, Bischoff P, Denis JM, Wambersie A and Jones D: Fast neutrons: Inexpensive and reliable tool to investigate high-LET particle radiobiology. Radiat Meas. 45:1414–1416. 2010. View Article : Google Scholar
12	Riccardi C and Nicoletti I: Analysis of apoptosis by propidium iodide staining and flow cytometry. Nat Protoc. 1:1458–1461. 2006. View Article : Google Scholar
13	Josset E, Burckel H, Noël G and Bischoff P: The mTOR inhibitor RAD001 potentiates autophagic cell death induced by temozolomide in a glioblastome cell line. Anticancer Res. 33:1845–1851. 2013.PubMed/NCBI
14	Altmeyer A, Josset E, Denis JM, Gueulette J, Slabbert J, Mutter D, Noël G and Bischoff P: The mTOR inhibitor RAD001 augments radiation-induced growth inhibition in a hepatocellular carcinoma cell line by increasing autophagy. Int J Oncol. 41:1381–1386. 2012.PubMed/NCBI
15	Rodriguez-Lafrasse C and Balosso J: From the carbon track to therapeutic efficiency of hadrontherapy. Cancer Radiother. 16:16–24. 2012.(In French). View Article : Google Scholar : PubMed/NCBI
16	Hada M and Georgakilas AG: Formation of clustered DNA damage after high-LET irradiation: a review. J Radiat Res. 49:203–210. 2008. View Article : Google Scholar : PubMed/NCBI
17	Hamada N, Imaoka T, Masunaga S, Ogata T, Okayasu R, Takahashi A, Kato TA, Kobayashi Y, Ohnishi T, Ono K, Shimada Y and Teshima T: Recent advances in the biology of heavy-ion cancer therapy. J Radiat Res. 51:365–383. 2010. View Article : Google Scholar : PubMed/NCBI
18	Tsuboi K, Moritake T, Tsuchida Y, Tokuuye K, Matsumura A and Ando K: Cell cycle checkpoint and apoptosis induction in glioblastoma cells and fibroblasts irradiated with carbon beam. J Radiat Res. 48:317–325. 2007. View Article : Google Scholar : PubMed/NCBI
19	Benzina S, Altmeyer A, Malek F, Dufour P, Denis JM, Gueulette J and Bischoff P: High-LET radiation combined with oxaliplatin induce autophagy in U-87 glioblastoma cells. Cancer Lett. 264:63–70. 2008. View Article : Google Scholar : PubMed/NCBI
20	Jiang YG, Peng Y and Koussougbo KS: Necroptosis: a novel therapeutic target for glioblastoma. Med Hypotheses. 76:350–352. 2011. View Article : Google Scholar
21	Todde V, Veenhuis M and van der Klei IJ: Autophagy: principles and significance in health and disease. Biochim Biophys Acta. 1792:3–13. 2009. View Article : Google Scholar
22	Hönscheid P, Datta K and Muders MH: Autophagy: detection, regulation and its role in cancer and therapy response. Int J Radiat Biol. Jun 25–2014.(Epub ahead of print). View Article : Google Scholar : PubMed/NCBI
23	Zois CE and Koukourakis MI: Radiation-induced autophagy in normal and cancer cells: towards novel cytoprotection and radio-sensitization policies? Autophagy. 5:442–450. 2009. View Article : Google Scholar : PubMed/NCBI
24	Zhuang W, Li B, Long L, Chen L, Huang Q and Liang Z: Induction of autophagy promotes differentiation of glioma-initiating cells and their radiosensitivity. Int J Cancer. 129:2720–2731. 2011. View Article : Google Scholar : PubMed/NCBI
25	Dumont FJ and Bischoff P: Disrupting the mTOR signaling network as a potential strategy for the enhancement of cancer radiotherapy. Curr Cancer Drug Targets. 12:899–924. 2012. View Article : Google Scholar : PubMed/NCBI
26	Bandhakavi S, Kim YM, Ro SH, Xie H, Onsongo G, Jun CB, Kim DH and Griffin TJ: Quantitative nuclear proteomics identifies mTOR regulation of DNA damage response. Mol Cell Proteomics. 9:403–414. 2010. View Article : Google Scholar :
27	Chen H, Ma Z, Vanderwaal RP, Feng Z, Gonzales-Suarez I, Wang J, Roti Roti JL, Gonzalo S and Zhang J: The mTOR inhibitor rapamycin suppresses DNA double-strand break repair. Radiat Res. 175:214–224. 2011. View Article : Google Scholar : PubMed/NCBI